For patients living with warm autoimmune hemolytic anemia (wAIHA), the disease has long been defined by a cycle of debilitating fatigue and precarious hemoglobin levels. Existing treatments, such as corticosteroids and general immunosuppressants, often suppress the entire immune system rather than addressing the specific immunoglobulin G (IgG) autoantibodies that drive the destruction of red blood cells. IMAAVY (nipocalimab-aahu) functions differently by selectively blocking the neonatal Fc receptor to reduce these pathogenic antibodies while preserving B-cell function.

The clinical case for this approval rests on the Phase 2/3 ENERGY study, which compared the drug against a placebo. Patients receiving IMAAVY showed a durable hemoglobin response, with data indicating that those on the treatment were roughly three times more likely to maintain healthy red blood cell levels over 24 weeks. Beyond the clinical markers, participants reported meaningful improvements in fatigue scores, a key indicator of quality of life for those suffering from the chronic nature of the anemia.

Dr. David Kuter of Massachusetts General Hospital noted that the therapy changes the treatment paradigm by providing a proven safety profile for an underserved community. While common side effects include peripheral edema, diarrhea, and fever, the drug’s ability to stabilize hemoglobin levels provides a significant shift for patients who have historically faced limited options. Johnson & Johnson plans to support patient access through its IMAAVY withMe program, which provides nurse navigation and cost assistance to those managing this rare condition.